Lebel, E., Abdulgawad, A., Bramanti, S., Garate, G., Ho, P. J., Keränen, M., Cohen, Y., Vase, M., Khot, A., Kristensen, I. B., LeBlanc, R., Lee, C., Legiec, W., Magen, H., Mateos, M., Oh, D., Pour, L., Schutz, N., Spyridonidis, A., Weisel, K., Zaucha, J., Larson, S., Varshasvsky, A., Grazioli, K., Basudhar, D., Hu, H., Meng, Y., Eldjerou, L., Bal, S., Harrison, S., Popat, R., Raab, M., Rodriguez-Otero, P. (2025). Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide. Blood. https://doi.org/10.1182/blood-2025-2302